<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904445</url>
  </required_header>
  <id_info>
    <org_study_id>NL</org_study_id>
    <nct_id>NCT04904445</nct_id>
  </id_info>
  <brief_title>COVID-19 Antibody Responses In Cystic Fibrosis</brief_title>
  <acronym>CAR-CF</acronym>
  <official_title>COVID-19 Antibody Responses In Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen's University, Belfast</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Cystic Fibrosis Society - Clinical Trial Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in&#xD;
      an ongoing global pandemic. It is unclear whether the relatively low number of reported cases&#xD;
      of COVID-19 in people with CF (pwCF) is due to enhanced infection prevention practices or&#xD;
      whether pwCF have protective genetic/immune factors. This study aims to prospectively assess&#xD;
      the proportion of pwCF, including both adults and children with CF who have evidence of&#xD;
      SARS-CoV-2 antibodies over a two-year period. This study will also examine whether pwCF who&#xD;
      have antibodies for SARS-CoV-2 have a different clinical presentation and what impact this&#xD;
      has on their CF disease. The proposed study will recruit pwCF from paediatric and adult CF&#xD;
      centres throughout the United Kingdom. Serological testing to detect antibodies will be&#xD;
      performed on blood samples taken at month 0, 6, 12, 18 and 24 with additional time-points if&#xD;
      bloodwork is available via normal clinical care. Clinical data on, lung function, CF-related&#xD;
      medical history, pulmonary exacerbations, antibiotic use, and microbiology and vaccination&#xD;
      receipt, will be collected during routine clinical assessments.&#xD;
&#xD;
      Associations will be examined between socio-demographic and clinical variables and serologic&#xD;
      testing. We will also examine the effects of SARS-CoV-2 infection on clinical outcomes and&#xD;
      analyse end-points to explore any age-related or gender-based differences, as well as&#xD;
      subgroup analysis of outcomes in lung-transplant recipients and pwCF receiving CFTR modulator&#xD;
      therapies. As pwCF receive COVID-19 vaccination we will perform a comparison of the&#xD;
      development and progression of anti-SARS-CoV-2 antibodies in pwCF following natural infection&#xD;
      and vaccination SARS-CoV-2 over time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, longitudinal cohort study in people with Cystic Fibrosis (pwCF) that&#xD;
      involves repeated serial sampling of participants. This study design was chosen to provide&#xD;
      comprehensive information on SARS-CoV-2 seroprevalence changes over time and the subsequent&#xD;
      clinical impact on pwCF. The study will be conducted at participating CF centres over a&#xD;
      3-year period. Study participants will include paediatric and adult pwCF. For the UK section&#xD;
      of the study, UK investigators in the European Cystic Fibrosis Society-Clinical Trials&#xD;
      Network (ECFS-CTN) will be invited to participate. Participating investigators can enrol all&#xD;
      eligible pwCF over a 12-month period. Participants are then followed up for 24 months.&#xD;
      Participants will donate blood samples at their routine clinic visits. Blood samples will be&#xD;
      collected at Day 0 (baseline), at Months 6, 12, 18 and 24 (to coincide with routine clinical&#xD;
      reviews). Additional blood samples will be taken opportunistically every time the participant&#xD;
      visits the clinic for blood draws. These blood samples could be related to, routine care,&#xD;
      annual review visits, pulmonary exacerbations (PEx), CF complications or when initiating new&#xD;
      treatments (e.g. CFTR modulators).&#xD;
&#xD;
      Serum from blood samples will be shipped to a central laboratory (Queen's University Belfast)&#xD;
      for standardized measurement of SARS-CoV-2 antibodies.&#xD;
&#xD;
      Alongside the blood samples the investigator will also collect clinical data from the&#xD;
      patient's health records and will input this data into the case report form (CRF). Clinical&#xD;
      data will be collected in conjunction with routine care visits, according to local clinical&#xD;
      practice. Investigators will collect data elements from information routinely recorded in the&#xD;
      patients' medical records. Data will be collected at baseline, month 6, 12, 18 and 24 as per&#xD;
      the study schedule, and at additional blood sampling timepoints as previously explained&#xD;
      above. Data collection will include routine data available from CF clinic follow-ups&#xD;
      including background demographic information, CF medical history, medications, exacerbation&#xD;
      information, sputum microbiology and clinical and lung function parameters. Information on&#xD;
      SARS-CoV-2 infection history and vaccine receipt will also be collected.&#xD;
&#xD;
      The maximum follow-up duration of participation in the study for each patient will be 24&#xD;
      months. This study duration (24-month follow-up) is justified as it provides sufficient time&#xD;
      to observe changes in antibody prevalence over the course of the COVID-19 pandemic as well as&#xD;
      sufficient time to determine long term clinical outcomes for pwCF who are SARS-CoV-2&#xD;
      seropositive. Furthermore, we anticipate the 2-year study follow-up period will provide&#xD;
      sufficient time to observe the impact of vaccination on antibody levels given that a number&#xD;
      of vaccines are now commercially available.&#xD;
&#xD;
      We will compare the level of antibody responses between natural COVID-19 infection and&#xD;
      vaccination in pwCF and how this varies over time. This will be achieved by analyzing&#xD;
      seroprevalence and antibody levels according to natural infection and vaccination status and&#xD;
      according to time of sample post infection or post vaccination, if known.&#xD;
&#xD;
      Optional Study sample collection:&#xD;
&#xD;
      For participants who consent, a second blood sample will also be drawn into EDTA tubes&#xD;
      (plasma). Consent to this optional study sample would allow this sample and any remaining&#xD;
      serum (following antibody testing) to be stored for future analysis and allow further&#xD;
      research to be carried out on related studies to COVID-19 and CF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate SARS-CoV-2 seroprevalence</measure>
    <time_frame>3-year period (comprising a 1-year enrollment period and a 2-year follow-up)</time_frame>
    <description>To evaluate SARS-CoV-2 seroprevalence in a cohort of people with cystic fibrosis, followed longitudinally over a 3-year period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To examine the associations</measure>
    <time_frame>3-year period (comprising a 1-year enrollment period and a 2-year follow-up)</time_frame>
    <description>To examine the associations between SARS-CoV-2 seropositivity, clinical symptoms and clinical outcomes in a cohort of people with cystic fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To perform a longitudinal comparison</measure>
    <time_frame>3-year period (comprising a 1-year enrollment period and a 2-year follow-up)</time_frame>
    <description>To perform a longitudinal comparison of the development and progression of anti-SARS-CoV-2 antibodies in people with cystic fibrosis following natural infection and vaccination SARS-CoV-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Storage of samples for future analysis</measure>
    <time_frame>anticipated 5-10 years</time_frame>
    <description>Storage of samples for future analysis on the impact of COVID-19 immune response in people with cystic fibrosis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cystic Fibrosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A 6-monthly blood sample will be collected when the participants attend clinic or hospital.&#xD;
&#xD;
      For participants who consent to the optional study, a second blood sample will also be drawn.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People with cystic fibrosis of any age, genotype, transplant status and disease severity at&#xD;
        sites across Europe will be eligible to participate in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consenting people with cystic fibrosis of any age, genotype, transplant status and&#xD;
             disease severity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to give informed consent&#xD;
&#xD;
          -  Contraindication to blood draw&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damian Downey, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Queen's University, Belfast</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hettie M Janssens, Dr</last_name>
    <phone>+31 (0)10 7036263</phone>
    <email>h.janssens@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edmond HH Rings, Prof.dr.</last_name>
    <phone>+31 (0)10 7036226</phone>
    <email>e.rings@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus Medical Center Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <state>South-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hettie Janssens, MD, PhD</last_name>
      <phone>+31 10 703 6263</phone>
      <email>h.janssens@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Badies Manaï, MSc</last_name>
      <phone>+31 10 706 6683</phone>
      <email>b.manai@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.ecdc.europa.eu/en/covid-19/latest-evidence/immune-responses</url>
    <description>European Centre for Disease Prevention and Control. Immune responses and immunity to SARS-CoV-2. Published 2020.</description>
  </link>
  <link>
    <url>https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html</url>
    <description>Centers for Diseases Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Updated Nov 3rd 2020.</description>
  </link>
  <reference>
    <citation>Abdollahi E, Champredon D, Langley JM, Galvani AP, Moghadas SM. Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States. CMAJ. 2020 Jun 22;192(25):E666-E670. doi: 10.1503/cmaj.200711. Epub 2020 May 22.</citation>
    <PMID>32444481</PMID>
  </reference>
  <reference>
    <citation>Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahon M, Simon V, Krammer F. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol. 2020 Jun;57(1):e100. doi: 10.1002/cpmc.100.</citation>
    <PMID>32302069</PMID>
  </reference>
  <reference>
    <citation>Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1. Erratum in: Nature. 2020 Dec;588(7839):E35.</citation>
    <PMID>32235945</PMID>
  </reference>
  <reference>
    <citation>Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. doi: 10.1093/cid/ciaa344.</citation>
    <PMID>32221519</PMID>
  </reference>
  <reference>
    <citation>Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski LH, Yu J, Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wrijil LM, Ducat S, Martinez DR, Atyeo C, Fischinger S, Burke JS, Slein MD, Pessaint L, Van Ry A, Greenhouse J, Taylor T, Blade K, Cook A, Finneyfrock B, Brown R, Teow E, Velasco J, Zahn R, Wegmann F, Abbink P, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kordana N, Li Z, Lifton MA, Mahrokhian SH, Maxfield LF, Nityanandam R, Nkolola JP, Schmidt AG, Miller AD, Baric RS, Alter G, Sorger PK, Estes JD, Andersen H, Lewis MG, Barouch DH. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 Aug 14;369(6505):812-817. doi: 10.1126/science.abc4776. Epub 2020 May 20.</citation>
    <PMID>32434946</PMID>
  </reference>
  <reference>
    <citation>Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020 Apr 4;395(10230):1101-1102. doi: 10.1016/S0140-6736(20)30788-1.</citation>
    <PMID>32247384</PMID>
  </reference>
  <reference>
    <citation>Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, Huang X, Lu S. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005 Feb;79(3):1906-10.</citation>
    <PMID>15650214</PMID>
  </reference>
  <reference>
    <citation>He Y, Zhou Y, Siddiqui P, Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52.</citation>
    <PMID>15530413</PMID>
  </reference>
  <reference>
    <citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.</citation>
    <PMID>31978945</PMID>
  </reference>
  <reference>
    <citation>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-544. doi: 10.1038/s41564-020-0695-z. Epub 2020 Mar 2.</citation>
    <PMID>32123347</PMID>
  </reference>
  <reference>
    <citation>Colombo C, Burgel PR, Gartner S, van Koningsbruggen-Rietschel S, Naehrlich L, Sermet-Gaudelus I, Southern KW. Impact of COVID-19 on people with cystic fibrosis. Lancet Respir Med. 2020 May;8(5):e35-e36. doi: 10.1016/S2213-2600(20)30177-6. Epub 2020 Apr 15.</citation>
    <PMID>32304639</PMID>
  </reference>
  <reference>
    <citation>Cosgriff R, Ahern S, Bell SC, Brownlee K, Burgel PR, Byrnes C, Corvol H, Cheng SY, Elbert A, Faro A, Goss CH, Gulmans V, Marshall BC, McKone E, Middleton PG, Ruseckaite R, Stephenson AL, Carr SB; Global Registry Harmonization Group. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros. 2020 May;19(3):355-358. doi: 10.1016/j.jcf.2020.04.012. Epub 2020 Apr 25.</citation>
    <PMID>32376098</PMID>
  </reference>
  <reference>
    <citation>Flight WG, Bright-Thomas RJ, Tilston P, Mutton KJ, Guiver M, Morris J, Webb AK, Jones AM. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax. 2014 Mar;69(3):247-53. doi: 10.1136/thoraxjnl-2013-204000. Epub 2013 Oct 14.</citation>
    <PMID>24127019</PMID>
  </reference>
  <reference>
    <citation>Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. 1984 Dec 27;311(26):1653-8.</citation>
    <PMID>6504106</PMID>
  </reference>
  <reference>
    <citation>Peckham D, McDermott MF, Savic S, Mehta A. COVID-19 meets Cystic Fibrosis: for better or worse? Genes Immun. 2020 Aug;21(4):260-262. doi: 10.1038/s41435-020-0103-y. Epub 2020 Jul 1. Review.</citation>
    <PMID>32606316</PMID>
  </reference>
  <reference>
    <citation>Wat D. Impact of respiratory viral infections on cystic fibrosis. Postgrad Med J. 2003 Apr;79(930):201-3. Review.</citation>
    <PMID>12743335</PMID>
  </reference>
  <reference>
    <citation>Bucher J, Boelle PY, Hubert D, Lebourgeois M, Stremler N, Durieu I, Bremont F, Deneuville E, Delaisi B, Corvol H, Bassinet L, Grenet D, Remus N, Vodoff MV, Boussaud V, Troussier F, Leruez-Ville M, Treluyer JM, Launay O, Sermet-Gaudelus I. Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy. BMC Infect Dis. 2016 Feb 1;16:55. doi: 10.1186/s12879-016-1352-2.</citation>
    <PMID>26830335</PMID>
  </reference>
  <reference>
    <citation>Stanton BA, Hampton TH, Ashare A. SARS-CoV-2 (COVID-19) and cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2020 Sep 1;319(3):L408-L415. doi: 10.1152/ajplung.00225.2020. Epub 2020 Jul 15.</citation>
    <PMID>32668165</PMID>
  </reference>
  <reference>
    <citation>Berardis S, Verroken A, Vetillart A, Struyf C, Gilbert M, Gruson D, Gohy S. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis. J Cyst Fibros. 2020 Nov;19(6):872-874. doi: 10.1016/j.jcf.2020.08.005. Epub 2020 Aug 11.</citation>
    <PMID>32828701</PMID>
  </reference>
  <reference>
    <citation>Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008 Aug;153(2):S4-S14. doi: 10.1016/j.jpeds.2008.05.005.</citation>
    <PMID>18639722</PMID>
  </reference>
  <reference>
    <citation>Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World Health Organ. 2011 Jan 1;89(1):46-53. doi: 10.2471/BLT.10.080010. Epub 2010 Sep 10. Review.</citation>
    <PMID>21346890</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. H.M. Janssens</investigator_full_name>
    <investigator_title>Pediatric Pulmonologist</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Seroprevalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

